Effects of CpG-ODNs on phenotype and function of monocyte-derived dendritic cells in chronic hepatitis B

Table 1 Effects of different immunologic adjuvants on expression levels of surface molecules (%) on DCs derived from blood monocytes of patients with chronic hepatitis B

Surface molecules	CpG	CpG + HBsAg	TNF-α	HBsAg	PBS
HLA-DR	93.8 ± 3.7a	95.1 ± 4.5a	94.8 ± 3.1	87.6 ± 4.3a	70.4 ± 3.9
CD86	83.7 ± 5.3	81.5 ± 3.2	82.3 ± 2.7	83.2 ± 3.6	80.2 ± 4.2
CD1a	12.0 ± 0.9	44.5 ± 1.2a	12.7 ± 1.9	15.0 ± 2.5	13.6 ± 0.8

DCs: Dendritic cells; CHB: Chronic hepatitis B; CpG-ODNs: Synthetic nonmethylated CpG-containing oligodeoxynucleotide; HBsAg: Hepatitis B surface antigen; PBS: Phosphate buffer solution; TNF: Tumor necrosis factor. HLA-DR, CD86 and CD1a are the specific surface molecules of DCs; CpG, CpG + HBsAg, TNF-α and HBsAg are the different adjuvants on DCs.

^aP ＜ 0.05 using Student’s t test, represents the stimulating effects of different immunologic adjuvants in comparison to control group (PBS).

Table 2 Supernatant IL-12p70 levels (ng/L) before and after the treatment with different immunologic adjuvants in dendritic cells derived from blood monocytes of patients with chronic hepatitis B

	CpG-ODN	TNF-α	CpG-ODN+HBsAg	TNF-α+ HBsAg	HBsAg	PBS
Before treatment	43.1 ± 40.9a	58.5 ± 52.2a	31.8 ± 65.4	20.4 ± 8.3	21.5 ± 14.2	36.3 ± 27.6
After treatment	103.6 ± 106.6a	98.70 ± 76.5a	81.4 ± 70.9	83.9 ± 76.5	13.9 ± 9.0	35.5 ± 31.8

^aP < 0.05 vs PBS. DCs: Dendritic cells; HBsAg: Hepatitis B surface antigen; CpG-ODN: Synthetic nonmethylated CpG-containing oligodeoxynucleotide; PBS: Phosphate buffer solution; TNF: Tumor necrosis factor. CpG, CpG + HBsAg, TNF-α, HBsAg and TNF-α + HBsAg are the different adjuvants on DCs. ^aP＜0.05 using Student’s t test, representing supernatant IL-12p70 levels of DCs from CHB before and after the treatment with different immunologic adjuvants in comparison to control group (PBS).